Peringatan Keamanan

Most common adverse reactions (incidence ?5% of subjects) were urticaria, rash nausea, pruritus and back pain FDA label.

Severe hypersensitivity reactions may occur with the use of CROFAB. In case of acute hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, discontinue infusion and institute appropriate emergency treatment FDA label.

CROFAB contains purified immunoglobulin fragments from the blood of sheep that have been immunized with snake venoms. Injection of heterologous animal proteins can lead to severe acute and delayed hypersensitivity reactions (late serum reaction or serum sickness) and a possible febrile response to immune complexes formed by animal antibodies and neutralized venom components.

Papain enzyme is used to cleave antibodies into fragments during the processing of CROFAB, and negligible amounts of papain or inactivated papain residues may be present. Patients allergic to papain, chymopapain, other papaya extracts, or the pineapple enzyme bromelain may also have an allergic reaction to CROFAB. Certain dust mite allergens and some latex allergens share antigenic structures with papain and patients with these allergies may be allergic to papain FDA label.

Crotalus atrox antivenin

DB13892

biotech approved experimental

Deskripsi

Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. The majority of people bitten are males and about 50% occur in the age group of 18 to 28 F113.

Crotalus atrox antivenin is derived and purified immunoglobulin fragments obtained from other domestic animals such as sheep previously immunized with Crotalus atrox (Western Diamondback rattlesnake). Bites from this snake are the most common in the state of Texas, USA A33157.

The final purified antivenin product is produced by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques. It is intravenously (IV) administered to prevent/limit systemic toxicity FDA label.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 12-23 hours [F113]
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

0 Data
Tidak ada data.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 9839686
    de Rezende NA, Torres FM, Dias MB, Campolina D, Chavez-Olortegui C, Amaral CF: South American rattlesnake bite (Crotalus durissus SP) without envenoming: insights on diagnosis and treatment. Toxicon. 1998 Dec;36(12):2029-32.
  • PMID: 9209225
    Seifert SA, Boyer LV, Dart RC, Porter RS, Sjostrom L: Relationship of venom effects to venom antigen and antivenom serum concentrations in a patient with Crotalus atrox envenomation treated with a Fab antivenom. Ann Emerg Med. 1997 Jul;30(1):49-53.
  • PMID: 10613947
    Rosen PB, Leiva JI, Ross CP: Delayed antivenom treatment for a patient after envenomation by Crotalus atrox. Ann Emerg Med. 2000 Jan;35(1):86-8.
  • PMID: 6367819
    Pandya BV, Budzynski AZ: Anticoagulant proteases from western diamondback rattlesnake (Crotalus atrox) venom. Biochemistry. 1984 Jan 31;23(3):460-70.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • CroFab
    Injection, powder, lyophilized, for solution • - • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul